Total sales for 2019 were $361 million, with the FDA only approving the drug for infants under the age of 2 in June.
About 200 patients have been treated with Zolgensma since its approval.
Priced at $2.1 million, Zolgensma provides a one-time treatment for the rare neurological disease and is the most expensive drug on the market.
Reimbursement agreements have been established with payers to cover 97 percent of patients with commercial plans and 50 percent of patients covered by Medicaid, according to Stat.
More articles on biologics:
Bundled payments in spine: 12 key thoughts for 2020
Breaking down the 3 major robots in spine surgery
8 spine, neurosurgeon moves
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
